LEJEUNE; Pascale

Patent Applications and Registrations

Patent applications and USPTO patent grants for LEJEUNE; Pascale.The latest application filed is for "combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates".

Company Profile

4.8.21

LEJEUNE; Pascale - Toulouse FR
LEJEUNE; Pascale - Berlin DE
LEJEUNE; Pascale - Vitry FR
LEJEUNE; Pascale - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination Of Pd-1/pd-l1 Inhibitors And Targeted Thorium Conjugates App 20220125960 - HAGEMANN; Urs Beat ; et al.	2022-04-28
Combination Of Ar Antagonists And Targeted Thorium Conjugates App 20220118123 - HAMMER; Stefanie ; et al.	2022-04-21
Binder/active Agent Conjugates Directed Against Cxcr5, Having Enzymatically Cleavable Linkers And Improved Activity Profile App 20210275686 - JOHANNES; Sarah Anna Liesa ; et al.	2021-09-09
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20190275147 - BISSERY; Marie-Christine ; et al.	2019-09-12
2,3-benzodiazepines Grant 9,890,147 - Siegel , et al. February 13, 2	2018-02-13
BET protein-inhibiting 5-aryltriazoleazepines Grant 9,663,523 - Schmees , et al. May 30, 2	2017-05-30
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Cyclophosphamide App 20170056496 - LEJEUNE; Pascale ; et al.	2017-03-02
Bet-protein-inhibiting Dihydropyridopyrazinones App 20160193206 - SCHMEES; Norbert ; et al.	2016-07-07
Bicyclo 2,3-benzodiazepines And Spirocyclically Substituted 2,3-benzodiazepines App 20160129011 - SIEGEL; Stephan ; et al.	2016-05-12
Antitumors combinations containing antibodies recognizing specifically CD38 and bortezomib Grant 9,314,522 - Deckert , et al. April 19, 2	2016-04-19
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan Grant 9,259,406 - Lejeune , et al. February 16, 2	2016-02-16
Pyrrolo- And Pyrazolo-triazolodiazepines As Bet-protein Inhibitors For Treating Hyperproliferative Diseases App 20160009725 - SCHMEES; Norbert ; et al.	2016-01-14
4-substituted Pyrrolo- And Pyrazolo-diazepines App 20150376196 - SCHMEES; Norbert ; et al.	2015-12-31
Bet Protein-inhibiting 5-aryl Triazole Azepines App 20150299201 - Schmees; Norbert ; et al.	2015-10-22
2,3-benzodiazepines App 20150203483 - Siegel; Stephan ; et al.	2015-07-23
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines App 20140213575 - Schmees; Norbert ; et al.	2014-07-31
Antitumors Combinations Containing Antibodies Recognizing Specifically CD38 And Bortezomib App 20140186337 - Deckert; Jutta ; et al.	2014-07-03
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20140127202 - BISSERY; Marie-Christine ; et al.	2014-05-08
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine Grant 8,633,301 - Lejeune , et al. January 21, 2	2014-01-21
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Cytarabine App 20120093806 - Lejeune; Pascale ; et al.	2012-04-19
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Cyclophosphamide App 20110305690 - Lejeune; Pascale ; et al.	2011-12-15
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Vincristine App 20110293606 - Lejeune; Pascale ; et al.	2011-12-01
Antitumor Combinations Containing Antibodies Recognizing Specifically Cd38 And Melphalan App 20110274686 - Lejeune; Pascale ; et al.	2011-11-10
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20100160233 - BISSERY; Marie-Christine ; et al.	2010-06-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.